Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Helsinn Out-Licenses China Rights for Cancer Care Drug to MundiPharma

publication date: Mar 30, 2015
Helsinn, a Swiss pharma focused on supportive cancer care, out-licensed China marketing and distribution rights for a appetite-enhancing drug to Mundipharma, a UK company. The drug, anamorelin, is a novel oral ghrelin receptor agonist currently completing clinical trials as a treatment for cancer anorexia-cachexia in patients suffering from non-small cell lung cancer. Mundipharma will have exclusive rights to anamorelin in China, Hong Kong and Macao, while Helsinn will retain rights elsewhere and be responsible for China approval. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital